Capsules in development and multi-omics analysis services.
Clinical capsule programs across indications, plus analytics to support discovery, monitoring, and reporting.
Clinical programs
Grouped by capsule program (one card per capsule).
LND 101
Multi-indicationOncology capsule program evaluated across multiple tumor types.
- Melanoma — Phase 2b
- Lung cancer — Phase 2b
- Pancreatic cancer — Phase 1
- Renal cancer — Phase 1 (completed)
- Breast cancer — Phase 1 (about to start)
LND 102
Multi-indicationNeurology and chronic-condition capsule program with trials in flight and planning.
- ALS — Phase 1
- Fibromyalgia — Phase 2 (planning)
- Parkinson's disease — Phase 1
- Metabolic Associated Steatotic Liver Disease (MASLD) — Program build
LND 103
In clinicTargeted capsule program advancing in psychiatry and metabolic care settings.
- Anorexia Nervosa — Phase 1
Analysis services
Sequencing and multi-omics support across microbiome and host outcomes.
Metagenomics analysis
Species- and strain-level profiling, quality control, and longitudinal comparisons.
Functional & EC analysis
Pathway, gene family, and enzyme commission (EC) profiling with interpretation-ready outputs.
Metabolites analysis
Targeted and untargeted metabolomics processing with cohort-level and paired analyses.
16S rRNA analysis
Community profiling, alpha/beta diversity, and differential abundance with clear reporting.